A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2018
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 18 Dec 2017 Status changed from suspended to discontinued.
- 27 Nov 2017 This trial has been completed in Sweden (End Date: 2017-11-10).
- 05 Aug 2017 This trial has been completed in Belgium.